Selective inhibition of MEK-1/PPAR-γ interactions has recently been proposed as a concept for treatment of cancer, inflammation, and metabolic disorders but has yet to gain significant acceptance [212]. This evidence concerns the gene MAP2K1 and metabolic disease.